There has been a century-long view in medicine that reproductive function in both men and women is intimately involved with mood regulation. The 19th century witnessed a proliferation of medical reports documenting beneficial effects on mood and behavior after medical or surgical manipulations of women's reproductive function. More recently, the results of several studies suggest that gonadal steroids do regulate mood in some women. Thus, there is considerable interest in the potential role of reproductive therapies in the management of depressive illness, including both classical and reproductive endocrine–related mood disorders. Future studies need to determine the predictors of response to hormonal therapies compared with traditional antidepressant agents, and to characterize the long-term safety and benefits of these therapies.

Keywords: women; depression; estrogen; progesterone; DHEA; antidepressants

Author affiliations: Behavioral Endocrinology Branch, National Institute of Mental Health, Bethesda, Md, USA

Address for correspondence: Peter J. Schmidt, MD, National Institute of Mental Health, Building 10, Room 3N238, 10 Center Dr MSC 1276, Bethesda MD 20892-1276, USA  
(e-mail: schmidtpt@intra.nimh.nih.gov)

Over a century ago, numerous case reports described the onset of mood and behavioral disorders in temporal association with altered reproductive function, as well as the dramatic remission of mood and behavioral symptoms following the resumption of normal menstruation. Indeed, treatment strategies frequently included efforts to either normalize menstruation or remove the reproductive organs of women with mental illness. Although interest in reproductive endocrine therapies for mood disorders has persisted throughout the past century, the specific role, if any, that reproductive endocrine interventions should play in the treatment of mood disorders is still unclear.

In this article, we will describe the recent history of reproductive endocrine therapies for mood disorders, review the biology of gonadal steroids that may be relevant to mood regulation, discuss the current role for reproductive endocrine therapies in both reproductive endocrine–related mood disorders and classical mood disorders, and review theories about the mechanisms of action of gonadal steroids in the treatment of these conditions. Finally, we will discuss the potential future role of these and related compounds in the treatment of mood disorders.

Background

The 19th century medical literature contained several presumptions about the pathophysiology of mood disorders in women largely based on anecdotal observations of reproductive endocrine dysfunction (eg, amenorrhea) in psychiatrically ill women.1-5 These inferences, in turn, were translated into therapeutics. Thus, numerous reports also documented the beneficial effects on mood and behavior associated with medical or surgical manipulations of a woman’s reproductive function.6-9 In addition to their interest in the role of reproductive function in psychiatry, medical researchers in the late 19th
The 20th century also developed an interest in glandular secretions and factors that potentially modify physiology. Early experiments in humans with preparations derived from animal glands including thyroid, adrenal, ovary, testes, and spleen provided the directions for the developing fields of endocrinology and immunology. In his seminal lecture in 1889, Brown-Séquard not only originated the formal study of endocrinology, but he reported the potential psychotropic effects of gonadal secretions. His description of the invigorating effects of testicular extracts resulted in a brief but widespread use of these compounds (as well as other interventions intended to increase the body’s testicular or seminal fluid levels) in a variety of therapeutic settings. In addition to extracts of both testes and ovaries, investigators experimented with extracts of the thyroid and adrenal glands in psychiatric patients. This interest in thyroid and adrenal extracts enjoyed more enduring success with the recognition of their beneficial effects in the treatment of myxedema and Addison’s disease, respectively. However, the widespread use of gonadal extracts ultimately met with criticism due to some disappointing results and the realization that these extracts were not the “fountain of youth.” Their subsequent clinical use was largely restricted to the treatment of menopause-related hot flushes (ovarian extracts). Nonetheless, the observation that ovarian extracts inhibited ovulation in rabbits was sufficient to maintain medical interest in the potential role of gonadal extracts for the control of human fertility. Efforts to improve techniques of extraction and purification of biologically active substances from the gonads were fueled by the hope that factors regulating reproductive function would be identified. By the late 1920s and early 1930s through the efforts of Allen and Doisy, Corner and Allen, as well as others, many gonadal steroids were isolated and characterized including estrone, estradiol, progesterone, and several androgens. Moreover, during the next 10 years, chemists identified modifications of the steroids that could alter their absorption (eg, acetylation) and potency (eg, addition of ethinyl group or removal of C-19 methyl group). These findings initiated a resurgence in the medical use of gonadal steroids. Estrogen replacement therapy (ERT) was used to treat menopausal symptoms in the 1930s, and oral contraceptives (OCs) were developed and first approved (ie, Enovid®) by the Food and Drug Administration (FDA) in 1960. The use of exogenous gonadal steroids in women was once again widespread, and several papers were published reporting the therapeutic benefits of these compounds in involutinal melancholia, premenstrual syndrome (PMS), and postpartum depression (PPD). However, their widespread usage was restricted after reports in the 1970s of increased rates of endometrial cancer secondary to unopposed ERT and increased rates of thrombosis and pulmonary emboli in women taking OCs. More recently, gonadal steroid therapy has gained popularity due in part to the reports of the enhanced safety of both ERT and OCs and the reported beneficial/disease protective effects of gonadal steroids on multiple organ systems including the musculoskeletal, cardiovascular, and central nervous systems. The discovery of several other factors involved in the control of reproduction also led to new drug development. The decapeptide gonadotropin-releasing hormone (GnRH) was isolated and sequenced in the 1970s, and the observation that continuous GnRH infusion resulted in the downregulation of pituitary GnRH receptors led to the development of several GnRH agonists. These agonists were used to suppress reproductive endocrine function in a variety of medical conditions including hormone-dependent cancers and endometriosis. In combination with gonadal steroids, preparations of GnRH agonists provided physicians with a strategy to control reproductive function and regulate the exposure to specific gonadal steroids without resorting to surgery. Thus physicians could selectively eliminate and/or replace reproductive factors considered to be the potential source of a medical or psychiatric problem.

**Selected abbreviations and acronyms**

- **BDNF**: brain-derived neurotrophic factor
- **CREB**: cyclic adenosine monophosphate response element-binding (protein)
- **DHEA**: dehydroepiandrosterone
- **ECT**: electroconvulsive therapy
- **ERT**: estrogen replacement therapy
- **FSH**: follicle-stimulating hormone
- **GnRH**: gonadotropin-releasing hormone
- **5-HT**: serotonin (5-hydroxytryptamine)
- **OC**: oral contraceptive
- **PMS**: premenstrual syndrome
- **PPD**: postpartum depression
- **SSRI**: selective serotonin reuptake inhibitor
Could gonadal steroids be involved in mood regulation?

Results from animal studies demonstrate that gonadal steroids influence several of the neuroregulatory systems thought to be involved in both the pathophysiology of affective disorders and the efficacy of antidepressant therapies. In some, but not all, experimental paradigms, estradiol has been observed to inhibit serotonin reuptake transporter (SERT) mRNA and decrease activity at serotonin (5-hydroxytryptamine) 5-HT1A receptors, consistent with some reported actions of antidepressants on serotonergic system function. Moreover, in one study estradiol and testosterone facilitated imipramine-induced downregulation of 5-HT2 receptors in the rat frontal cortex. In addition to classic neurotransmitter systems, several candidate neural signaling systems have been identified as potential mediators of the therapeutic actions of antidepressants and electroconvulsive therapy (ECT) (eg, cyclic adenosine monophosphate [cAMP] response element-binding [CREB] protein and brain-derived neurotrophic factor [BDNF]) based on observations that these systems are modulated by a range of therapies effective in depression (eg, serotonergic and noradrenergic agents and ECT) and exhibit a pattern of change consistent with the latency to therapeutic efficacy for most antidepressants. For example, antidepressants increase the expression and activity of CREB in certain brain regions (eg, hippocampus) and regulate (in a brain region–specific manner) activity of genes with a cAMP response element. Genes for BDNF and its receptor trkB have been proposed as potential targets for antidepressant-related changes in CREB activity. Similarly, estradiol has been reported to influence activity of many of these same neuroregulatory processes. Specifically, ovariectomy has been reported to decrease, and estradiol increase, BDNF levels in the forebrain and hippocampus. Estrogen also increases CREB activity and trkA in the rat brain. In contrast, an estradiol-induced decrease in BDNF has been reported to mediate estradiol’s regulation of dendritic spine formation in hippocampal neurons. Thus, the therapeutic potential of gonadal steroids in depression is not only suggested by their widespread actions on neurotransmitter systems, but also by certain neuroregulatory actions shared by both estrogen and traditional therapies for depression (ie, antidepressants, ECT).

Reproductive endocrine–related mood disorders

Reproductive endocrine–related mood disorders refer to depressive-like disorders in which the appearance of mood disturbances occurs in temporal association with a change in reproductive function, and includes mood disorders occurring in association with the luteal phase of the menstrual cycle, the postpartum, and the perimenopause. Given the apparent association between the onset of mood disturbance and the change in reproductive function, these conditions have been suggested to develop secondary to some abnormality in ovarian hormone secretion, and reproductive therapies have been used in an attempt to correct the presumed endocrine anomaly.

Premenstrual syndrome

PMS is a condition characterized by cyclic changes in symptoms (including irritability, sadness, and anxiety) that interfere with daily function and are confined to the luteal phase of the menstrual cycle, with symptom remission occurring within a few days of the onset of menses. No diagnosis-related differences in reproductive hormones have been consistently observed during the luteal phase that would distinguish a woman with PMS from a woman without PMS. Despite the lack of evidence of ovarian dysfunction in women with PMS, the association of PMS symptoms with the luteal phase of the menstrual cycle perpetuated clinicians’ views that an abnormality of corpus luteum function caused PMS. Thus, multiple trials were conducted involving the administration of progesterone or progestin in women with PMS. However, the widespread use of progesterone in women with PMS was considerably diminished by the results of several recent studies: first, two large double-blind, placebo-controlled trials of natural progesterone (both suppository and oral forms) definitively demonstrated the lack of efficacy of progesterone compared with placebo in PMS. Second, a study employing a progesterone receptor antagonist, RU-486, with or without human chorionic gonadotropin, demonstrated that the normal symptoms of PMS could occur independently of the luteal phase of the menstrual cycle and, therefore, a luteal phase abnormality as a cause of PMS was no longer tenable.
The belief that PMS reflected a disturbance in ovarian function led to several trials of OCs to suppress or regulate ovarian function in this condition. Earlier cross-sectional studies suggested that women using OCs experienced fewer PMS symptoms than nonusers. However, studies also reported the opposite, and most results demonstrated that women on OCs reported fewer physical symptoms (ie, breast pain, bloating), but did not report fewer or less severe mood symptoms than nonusers. In fact, similar prevalence rates of cyclic mood symptoms regardless of OC use were prospectively documented by Sveindottir et al, with 2% to 6% of women meeting criteria for severe PMS in both OC users and nonusers. Moreover, observations suggest that the severity of mood symptoms do not vary with different preparations of OCs (eg, monophasic versus triphasic); however, one study did observe that the progestin desogestrel (reported to have less androgenic activity) was associated with fewer mood symptoms than levonorgestrel. Despite similar prevalence rates of negative mood symptoms in OC users and nonusers, some clinic-based studies suggested that a subgroup of women with PMS reported an improvement in mood symptoms while on OCs. None of the recent controlled trials of OCs in PMS have observed significant improvement (or worsening) in mood symptoms relative to placebo. However, these trials did observe significant reductions in symptom severity on OCs compared with placebo for some physical and behavioral symptoms, including loss of libido, breast pain, and bloating, and increased appetite and food cravings. Thus, neither cross-sectional studies nor controlled trials support a role for any formulation of OCs (tested to date) in the treatment of PMS.

Investigators have also examined the efficacy in PMS of estradiol (without the progestin contained in OCs) or testosterone. Trials of supraphysiologic doses of estradiol with or without testosterone have documented beneficial effects compared with placebo in women with PMS. Preliminary reports suggest that lower (more physiologic) doses of testosterone alone may also be effective in the treatment of PMS. Lower doses of estrogen, however, are no more effective than placebo and, therefore, it is possible that the therapeutic benefits of the higher dose estrogens are secondary to the suppression of ovulation. Nevertheless, one cannot infer the efficacy of these compounds to be secondary to ovarian suppression alone, given the lack of efficacy of OCs, which also inhibit ovulation, and the reported efficacy of compounds such as danazol when administered after ovulation in at least one study. Several open trials of ovarian suppression, induced surgically or medically, have reported the beneficial effects of this strategy in the treatment of PMS. Most, but not all, placebo-controlled trials of GnRH agonists (eg, leuprolide acetate) in PMS have reported the therapeutic efficacy of GnRH agonist–induced ovarian suppression compared with placebo. We observed significant reductions in PMS symptom severity during leuprolide treatment for all symptoms measured. In many of the trials, the degree of individual response to GnRH agonist varied considerably, despite evidence of a beneficial response to ovarian suppression on a group basis. We observed a response rate of approximately 60% employing relatively conservative criteria (ie, the absence within a 2-month time period of 2-weekly mean scores on anxiety, depression, or irritability greater than 2.5 on a 6-point scale). Similarly, Freeman et al reported that 67% of women with PMS responded to GnRH agonist–induced ovarian suppression. Response rates did not differ depending on the presence or absence of a past history of affective disorder in our sample of women with PMS. However, Freeman et al observed that the presence of persistent depressive symptoms throughout the menstrual cycle was associated with nonresponse to GnRH agonists. The reported response rates to selective serotonin reuptake inhibitors (SSRIs) in women with PMS (40%–60%) appear similar to the rates observed in trials of GnRH agonists. Thus, although the majority of studies would support the short-term use of GnRH agonists or SSRIs in this condition, symptomatic response is not uniform even to complete ovarian suppression. Moreover, it has not been determined whether the group of women with PMS who are responsive to SSRIs differs from those responsive to hormonal therapies. The factors that predict response to both therapies need to be identified, and these data may reveal further information about the pathophysiology of PMS.

The possibility that PMS reflects an abnormal mood and behavioral response to normal changes in ovarian steroid secretion has been suggested by several studies. We observed the precipitation of typical PMS symptoms after the administration of physiologic doses of either estradiol or progesterone in a group of women whose PMS symptoms were otherwise eliminated by ovarian suppression.
suppression with a GnRH agonist. Asymptomatic women who had no history of PMS undergoing the same hormonal manipulations showed no disturbance of mood during either hypogonadal conditions or hormonal addback. It would appear, therefore, that women with PMS are differentially sensitive to the mood-perturbing effects of gonadal steroids, as similar steroid manipulations in women without a history of PMS were without effect on mood.

The efficacies of both GnRH agonists and high-dose estrogen therapy in the treatment of PMS and the lack of efficacy of most OCs suggest that continuous steady-state levels of gonadal steroids may prevent the cyclic symptoms of PMS. Thus, the prolonged use of active OCs continuously may provide an additional treatment for some women with PMS. Nevertheless, typical PMS symptoms would be predicted to emerge if hormones are withdrawn and then read ministered. Trials of steady-state hormonal therapy are underway and may lead to an effective treatment for PMS as an alternative to traditional SSRIs.

Perimenopausal depression

Perimenopausal depression is a condition defined by the onset of depression at middle age in association with the onset of menstrual cycle irregularity or amenorrhea. Perimenopausal reproductive status is confirmed by the presence of menstrual cycle irregularity (or amenorrhea of less than 1 year’s duration) and hormonal evidence of ovarian dysfunction. This latter criterion has been operationalized to include either a single elevated plasma follicle-stimulating hormone (FSH) level or more persistent elevations of plasma FSH levels (eg, three out of four ≥14 IU/L). The Diagnostic and Statistical Manual of Mental Disorders 4th edition (DSM-IV) includes neither perimenopausal depression as a distinct mood disorder nor the perimenopause as a course specifier (as it does the postpartum period). Perimenopausal depressions may not be distinguished from major depressive disorder on the basis of phenomenology, course, family, or personal history of mood disorder, but they do appear to be distinct in their treatment response characteristics; specifically, they are responsive to ERT in contrast to depressions either before or after the perimenopausal phase. Despite the coincident timing of the onset of depression and the perimenopause, there has been no consistent evidence suggesting that perimenopausal depressed women can be distinguished from asymptomatic perimenopausal women on the basis of abnormalities of ovarian estrogens or androgens. Nonetheless, there have been several therapeutic trials of ERT in perimenopausal and postmenopausal women with depression.

Controlled studies employing synthetic forms of estrogen in the treatment of depression have yielded mixed results. Estrogen has been reported to improve mood (albeit inconsistently) in the following samples: (i) perimenopausal and postmenopausal women reporting depressive symptoms; (ii) postmenopausal women with depression unresponsive to traditional antidepressant therapy; and (iii) nondepressed menopausal women not experiencing hot flushes. We examined the therapeutic efficacy of estradiol replacement in 34 women (approximately half of whom had no prior history of depression) with perimenopausal depression under double-blind, placebo-controlled conditions. After 3 weeks of estradiol, depression rating scale scores were significantly decreased compared with baseline scores and significantly lower than scores in the women receiving placebo. A full or partial therapeutic response was seen in 80% of subjects on estradiol and in 22% of those on placebo, consistent with the observed effect size in a recent meta-analysis of studies examining estrogen’s effects on mood. The therapeutic response to estrogen was observed in both major and minor depression as well as in women with and without hot flushes. Finally, neither baseline nor posttreatment estradiol levels predicted therapeutic response. These data suggest that estrogen’s effect on depression is not solely a product of its ability to reduce the distress of hot flushes. Our findings are consistent with data from Montgomery et al and Saletu et al suggesting the beneficial effects of estrogen on mood in perimenopausal women reporting depressive symptoms. Two recent studies, by Soares et al and Morrison et al (personal communication) have extended these observations. First, Soares et al reported a significant and beneficial effect of ERT compared with placebo in women with perimenopause-related major depression (as defined by the Primary Care Evaluation of Mental Disorders [PRIME-MD]) and, additionally, reported that baseline plasma estradiol levels did not predict response to estrogen treatment. Second, Morrison et al observed that estrogen was no more effective than placebo in postmenopausal...
Clinical research

depressed women in contrast to previous results in perimenopausal women. These data emphasize that the stage of reproductive senescence may predict response to estrogen, as originally reported by Appleby et al.142 Thus, perimenopausal women who are undergoing changes in reproductive function may be more responsive to estrogen than postmenopausal women whose hormonal changes have long since stabilized.

Postpartum depression

PPD is defined in the DSM-IV128 as the onset of a depressive disorder within 4 weeks after delivery. The symptoms of depression during the postpartum are not distinct from depressions occurring at other periods of life, and the temporal association of symptoms with the postpartum period is the critical diagnostic feature, similar to perimenopausal depression. PPDs are not associated with an abnormality of reproductive function143; nonetheless, women with a history of PPD display an abnormal mood response to changes in reproductive hormones simulating endocrine events occurring at delivery.144 Despite the absence of endocrine abnormalities in this condition, there has been interest in whether supplementing reproductive endocrine function during the immediate postpartum could prevent or diminish depression.

Open studies of progesterone for the treatment of PPD were conducted by Dalton,145 who reported a reduced recurrence rate of postnatal depression in women using prophylactic progesterone compared with untreated women.146 Nonetheless, as with studies of progesterone in PMS, the absence of controlled trials examining the efficacy of progesterone in PPD limited the utility of Dalton’s observations. In fact, one double-blind, placebo-controlled study of 180 postpartum women, treated with either norethisterone enanthate or placebo, showed an increased risk of developing depressive symptoms following treatment with norethisterone.147 Thus, as with PMS, current evidence does not support a role for progesterone in the treatment of PPD.

Similar to earlier reports of progesterone’s efficacy, an open trial in women at risk for puerperal psychosis demonstrated that high-dose estrogen treatment resulted in a lower than expected 1-year relapse rate (9% compared with an expected 35%–60% without prophylaxis).148 Varying doses of estrogen (Premarin® ranging in dose from 0.625 to 10 mg per day or IV estradiol 25 mg every 8 hours) were administered immediately postpartum and then tapered over 4 weeks. It was suggested that estrogen administration could attenuate the rapid puerperal drop in estradiol levels, thereby reducing the negative impact of the postpartum “estrogen withdrawal state” on mood. In a follow-up study, Gregoire et al149 tested the suggestion that estradiol withdrawal caused PPD in a double-blind, placebo-controlled study of estradiol in 61 women who developed major depression within 3 months of delivery. Eighty percent of the patients receiving estrogen patch experienced a significant reduction in depression severity after 3 months of treatment, compared with 31% of the placebo-treated group. Reductions in mood symptoms on estrogen therapy were observed in women regardless of concurrent antidepressant use, and estrogen’s antidepressant effects were rapid and observed after 2 to 3 weeks of treatment. A similar rapid response to estradiol was also recently reported in an open-label trial of sublingual estradiol,150 similar to the timing of the response to estradiol in perimenopausal depression.

Classical mood disorders

In contrast to reproductive endocrine–related mood disorders, classical mood disorders, with few exceptions, have a more tenuous relationship with reproductive endocrine change. Several relationships have been proposed to explain reported observations. First, alterations in reproductive function may modulate the course or appearance of mood disorders. For example, investigators have described the menstrual cycle–related exacerbation or modulation of the symptoms of depressive and anxiety disorders, as well as bipolar illness.151 It is possible, therefore, that reproductive therapies would influence the course of these conditions.152 Indeed, clinical anecdotes describe the therapeutic benefits of ovarian suppression with GnRH agonists in women with menstrual cycle–entrained rapid cycling bipolar illness. Second, the hormonal accompaniments of aging, some of which involve reproductive hormones, may influence the onset of depression. Late- and midlife-onset depressions occur in the context of declining adrenal androgen secretion and reproductive senescence, and, therefore, the replacement of these reproductive hormones in late- and midlife-onset depressions may have a role in their treatment.152,153 Finally, gonadal steroids may modify the treatment response characteristics of subjects treated with conventional antidepressants. Some152,154 but not all155
studies have reported that the administration of estrogen enhances the therapeutic response to certain psychotropic agents including SSRIs. Additionally, altered reproductive endocrine function may result in disturbances in certain target symptoms, such as loss of libido, that occur in association with depression, but are not part of its presentation. Such symptoms, for example, may be responsive to androgen replacement but not antidepressant therapy. Similarly, androgen therapy may be effective in treating loss of libido occurring as a side effect of antidepressants.

**Midlife depression**

Midlife in both men and women is characterized by a steady decline in the production of androgens such as dehydroepiandrosterone (DHEA) and androstenedione, which are mostly of adrenal origin yet contribute up to 50% to circulating androgen levels (testosterone, dihydrotestosterone) in women. Declining plasma levels of testosterone in aging women may be less dramatic due to continued secretion of testosterone by the postmenopausal ovary. We examined the effects of the adrenal androgen DHEA on mood in women with midlife-onset depression in a double-blind, placebo-controlled, crossover design study. Preliminary results are consistent with previous studies by Wolkowitz et al and suggest the antidepressant efficacy of DHEA: DHEA, but not placebo, significantly improved depression ratings after 6 weeks of treatment (Daly et al, unpublished data). Plasma testosterone levels increased by approximately 30% after DHEA treatment (Smith et al, unpublished data). However, baseline plasma levels of DHEA or metabolites of DHEA (estradiol and testosterone) and mood were not correlated, and the lack of correlations between therapeutic response and baseline DHEA levels emphasizes our inability to infer that midlife depression in any way reflects a deficiency of reproductive hormones (Daly et al, personal communication).

**Mood disorders in the context of medical illness**

Several studies have suggested a potential role of hypogonadism in the mood symptoms and low energy present in some women with human immunodeficiency virus (HIV) infection. Trials of DHEA in women and other androgens such as testosterone in men with HIV have reported mood improvements. Although these reports may suggest a psychotropic effect of gonadal steroids in these subjects, the improved mood may also reflect the anabolic effects of these steroids. Improved muscle strength and weight changes in these subjects may improve energy level and, therefore, indirectly improve mood.

**Potential mechanisms of antidepressant action of gonadal steroids**

Several mechanisms may underlie the antidepressant effects of reproductive therapies in women. First, gonadal steroid supplements may correct a pathological deficiency of a particular gonadal steroid. However, in the majority of studies where gonadal steroids have been reported to be effective, the condition is neither associated with a particular abnormality of reproductive hormones nor are levels of reproductive hormones predictive of subsequent response to the therapeutic intervention. Nonetheless, local tissue metabolism of gonadal steroids (eg, aromatization of androgens) may produce a wide range of gonadal steroid levels within specific tissues. Thus, local and tissue-specific “relative” deficiencies of reproductive hormones could exist and cause symptoms, but not be identified by simply measuring plasma hormone levels. Second, studies of the effects of ERT in osteoporosis suggest the presence of a threshold of circulating estradiol above which therapeutic effects are observed, and it is possible that a similar phenomenon (ie, critical threshold) is operational in reproductive hormone–related effects on mood. For example, in women with premenstrual syndrome, a threshold of gonadal steroid levels may exist above which mood instability occurs, and, therefore, ovarian suppression with low level gonadal steroid replacement may produce mood stability. Additionally, there may be a critical threshold of estradiol or DHEA levels below which symptoms develop in some women, and the replacement of these hormones may elevate hormone levels sufficiently to produce a mood-enhancing effect. Third, the rate of change in hormone level may convey information and trigger mood changes in women who have a differential sensitivity to increasing (eg, PMS) or decreasing (eg, perimenopausal or postpartum depression) levels of gonadal steroids. Although basal hormone abnormalities do not characterize most women with reproductive endocrine–related mood disorders or classical mood disorders, diagnosis-related differences in the rapidity of the decline in
gonadal steroids during the postpartum or during the perimenopause may contribute to the onset of mood symptoms, a phenomenon that would not readily be identified in cross-sectional studies. Gonadal steroid replacement, therefore, could attenuate the rate of change of gonadal steroids in these subjects and prevent the occurrence of depression. Finally, it is possible that a direct psychotropic effect of gonadal steroids may be involved in their antidepressant efficacy. For example, the efficacy of estradiol in perimenopausal depression126,128 and reports (in some126,127 but not all128 studies) of estrogen augmenting the therapeutic efficacy of SSRIs suggest that estrogen may be acting pharmacologically, like other antidepressants, to alter the function of the central serotonin system.129-131 Roca et al132 have attempted to identify a possible role of serotonin in the antidepressant efficacy of ERT in perimenopause-related depression by employing the serotonin receptor antagonist metergoline. Perimenopausal depressed women who had previously demonstrated a remission of their mood symptoms on estradiol but not placebo were placed on open estrogen treatment. Subjects were administered metergoline or active placebo (benadryl) in a double-blind, crossover design. Depressive symptoms but not hot flushes returned 24 hours after metergoline administration. These changes in symptoms were not seen after placebo administration. These data suggest that the psychotropic effects of estradiol in depression may be mediated through the serotonin receptor subtypes antagonized by metergoline. The specific mechanisms underlying the therapeutic effects of reproductive therapies await the development of more specific antagonists of receptors for both gonadal steroids and neural systems such as the serotonin system.

Future directions

Advances in reproductive therapies for non–mood-related conditions should further the development of compounds whose pharmacologic actions are more specific and clearly defined and, therefore, will assist in efforts to determine the mechanisms of efficacy of reproductive hormones and their analogs in mood disorders in women. Receptor antagonists are available currently for each of the members of the family of steroid receptors. However, efforts to identify and characterize the mechanisms mediating the antidepressant response to gonadal steroids require the development of gonadal steroid receptor antagonists that reliably cross the blood–brain barrier and display receptor-subtype and brain-region specificity. Such compounds, for example, will facilitate investigations into the roles of estrogen receptors alpha and beta in the psychotropic actions of estradiol. Indeed, recent work by Krezel et al137 suggest that estrogen receptor beta, but not alpha, plays a prominent role in anxiety in rodents. Selective gonadal steroid receptor modulators are being developed for each of the gonadal steroid receptors, estrogen alpha and beta, progesterone, and androgen, and will provide a new generation of hormonal therapies that could provide more selective and targeted therapeutic effects. For example, beta-estrogen receptor–selective ligands may have differing effects on cognition than estradiol given the relatively higher concentration of estrogen receptor beta than alpha in the hippocampus.138,139 Additionally, selective androgen receptor modulators (SARMs),140 selective estrogen receptor modulators (SERMs),141 and selective progesterone receptor modulators (SPRMs)142,143 may display a more acceptable profile of long-term side effects (eg, lack of activity of SARMs at the prostate144) and permit their use on a more chronic basis. A potential advantage of reproductive hormonal therapies over conventional antidepressants is suggested by studies reporting the medical sequelae of depression including disorders of metabolism, the musculoskeletal system, and the cardiovascular system.145,146 Given the strong association of some of these disorders with deficient or abnormal reproductive endocrine activity,147 reproductive therapies of depression might prevent or reverse some of the medical sequelae in addition to improving mood. Finally, effects of reproductive therapies on the vascular endothelium and local blood flow may contribute to therapeutic effects of these compounds (eg, estradiol or DHEA) in certain conditions where deficits in the vascular system are thought to mediate the primary mood problem, such as in the vascular depressions described in the late-onset mood disorders.149

Conclusions

Compared with studies performed in the 1800s and to some extent the 1940s and 1950s, recent trials of reproductive endocrine therapies in mood disorders in women have employed more selective pharmacologic compounds, more rigorous study designs, and in some studies
REFERENCES

1. Barrus C. Gynecological disorders and their relation to insanity. Am J Psychiatry. 1895;51:475-491.
2. Sutherland H. Menstruation and insanity. In: Tuke DH, ed. A Dictionary of Psychological Medicine. Philadelphia, PA: Blakiston P, Son & Co; 1892:801-808.
3. Esquirol E. Des maladies mentales considérées sous les rapports médicaux, hygiéniens et médico-légaux. Paris, France: JB Bailliére; 1838.
4. English Lunacy Commissioners: Annual Reports to the Lord Chancellor. 1885-1901. London, UK: ELC; 1885.
5. Barnes F. On some psychological consequences of suppressed menstruation, 1896-1897. Br Gynaecol Soc. 1896;12:174-179.
6. Newbecker MM. The menstrual function in insane patients and the effects of ovariotomy. West Med Rev. 1897;2:169-171.
7. Meyer A. On the diseases of women as a cause of insanity, in the light of observations in sixty-nine autopsies. Trans Ill Med Soc. 1895;299-311.
8. Carpenter EG. Pelvic disease as a factor in insanity of females and surgery as a factor of cure. JAMA. 1900;35:545-551.
9. Savage GH. Some mental disorders associated with the menopause. Lancet. 1893;ii:1128.
10. Easterbrook CC. Organo-therapeutics in mental diseases. BMJ. 1900;2:813-823.
11. Brown-Séquard CE. The effects produced on man by subcutaneous injections of a liquid obtained from the testicles of animals. Lancet. 1889;2:105-107.
12. Herman JR. Rejuvenation: Brown-Séquard to Brinkley. Monkey glands to goat glands. N Y State J Med. 1982;82:1731-1739.
13. Aminoff MJ. Brown-Séquard: a Visionary of Science. New York, NY: Raven Press; 1993.
14. Schmidt P. Théorie und Praxis der Steinachschen Operation. Munich, Germany: Rikola Verlag; 1922.
15. Wilson JD. Charles-Edouard Brown-Séquard and the centennial of endocrinology. J Clin Endocrinol Metab. 1990;71:1403-1409.
16. Fosbery WHS. Severe climacteric flushings successfully treated by ovarian extract. BMJ. 1897;1:1039.
17. Fellenor O. Experimentell erzeugte Wachstumsveränderungen am weiblichen Genitale der Kaninchen. Zentralbl Allg Pathol Anat 1912;23:673-676.
18. Allen E, Doisy EA. An ovarian hormone: preliminary report on its location, extraction and partial purification, and action in test animals. JAMA. 1923;81:819-821.
19. Corner GW, Allen WM. Physiology of the corpus luteum. II. Production of a special uterine reaction (progestational propagation) by extracts of the corpus luteum. Am J Physiol. 1929;88:326-346.
20. Colton FB. Steroids and “the pill”: early steroid research at Searle. Steroids. 1992;57:624-630.
21. Goldzieher JW. The history of steroidal contraceptive development: the estrogens. Perspect Biol Med. 1993;36:363-368.
22. Perone N. The history of steroidal contraceptive development: the progestins. Perspect Biol Med. 1993;36:347-362.
23. Ettinger B. Overview of estrogen replacement therapy: a historical perspective. Proc Soc Exp Biol Med. 1998;217:2-5.
24. Werner AA, Johns GA, Hoster EF, Ault CC, Kohler LW, Weis MW. Involutional melancholia: probable etiology and treatment. JAMA. 1934;103:13-16.
25. Sevinghaus EL. The use of folliculin in involutional states. Am J Obstet Gynecol. 1933;25:361-368.
26. Dalton K. Comparative trials of new oral progestogenic compounds in treatment of premenstrual syndrome. BMJ. 1959;1307-1309.
27. Israel S. Premenstrual tension. JAMA. 1938;110:1721-1723.
28. Schmidt H. The use of progesterone in the treatment of post-partum psychosis. JAMA. 1943;190-192.
29. Bower WH, Altschule MD. Use of progesterone in the treatment of post-partum psychosis. N Engl J Med. 1956;254:157-160.
30. Kane FJ Jr, Keeler MH. The use of enovid in postpartum mental disorders. South Med J. 1965;58:1089-1092.
31. Fraser IS. Forty years of combined oral contraception: the evolution of a revolution. Med J Aust. 2000;173:541-544.
32. Burkman RT, Collins JA, Shulman LP, Williams JK. Current perspectives on oral contraceptive use. Am J Obstet Gynecol. 2001;185:S4-S12.
33. Felson DT, Zhang Y, Hannan MT, Kiel DP, Wilson PWF, Anderson JJ. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med. 1993;329:1141-1146.
34. Birge SJ, McEwen BS, Wise PM. Effects of estrogen deficiency on brain function. Implications for the treatment of postmenopausal women. Postgrad Med. 2001;Spec No:11-16.
35. Stein DG. Brain damage, sex hormones and recovery: a new role for progestosterone and estrogen? Trends Neurosci. 2001;24:386-391.
36. Jensen JT, Speroff L. Health benefits of oral contraceptives. Obstet Gynecol Clin North Am. 2000;7:705-721.
37. King JA, Millar RP. Evolution of gonadotropin-releasing hormones. Trends Endocrinol Metab. 1992;3:339-346.
38. Matsuo H, Baba Y, Nair RMG, Arimura A, Schally AV. Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence. Biochem Biophys Res Commun. 1971;43:1334-1339.
39. Vickery BH. Comparison of the potential for therapeutic utilities with gonadotropin-releasing hormone agonists and antagonists. Endocr Rev. 1986;7:115-124.
40. Casper RF. Clinical uses of gonadotropin-releasing hormone analogues. Can Med Assoc J. 1991;144:153-158.
41. Woolley CS, Schwartzkroin PA. Hormonal effects on the brain. Epilepsia. 1998;39:52-58.
42. Naftolin F, Leranth C, Horvath TL, Garcia-Segura LM. Potential neuronal mechanisms of estrogen actions in synaptogenesis and synaptic plasticity. Cell Mol Neurobiol. 1996;16:213-223.
43. McEwen BS, Woolley CS. Estradiol and progesterone regulate neuronal structure and synaptic connectivity in adult as well as developing brain. Exp Gerontol. 1994;29:431-436.
44. McEwen BS, Alves SE, Bulloch K, Weiland NG. Ovarian steroids and the brain: implications for cognition and aging. Neurology. 1997;48(suppl 7):S8-S15.
45. Rachman IM, Unnerstall JR, Pfaff DW, Cohen RS. Estrogen alters behavior and forebrain c-fos expression in ovariectomized rats subjected to the forced swim test. Proc Natl Acad Sci U S A. 1998;95:13941-13946.
46. Rubinow DR, Schmidt PJ, Roca CA. Estrogen-serotonin interactions: implications for affective regulation. Biol Psychiatry. 1998;44:839-850.
47. Pecins-Thompson M, Brown NA, Bethea CL. Regulation of serotonin reuptake transporter mRNA expression by ovarian steroids in rhesus macaques. Brain Res Mol Brain Res. 1998;53:120-129.
48. Clarke WP, Maayani S. Estrogen effects on 5-HT 1A receptors in hippocampal membranes from ovariectomized rats: functional and binding studies. Brain Res. 1990;518:287-291.
49. Thomas ML, Bland DA, Clarke CH, Cunningham KA. Estrogen regulation of serotonin (5-HT) transporter and 5-HT 1A receptor mRNA in female rat brain. Actaer Soc Neurosci. 1997;23:1501.
Tratamientos con hormonas de la reproducción para los trastornos del ánimo en las mujeres

Desde hace más de un siglo en la medicina ha existido la visión que la función reproductora tanto en los hombres como en las mujeres está íntimamente relacionada con la regulación del ánimo. El siglo XIX fue testigo de una proliferación de informes médicos en que se documentaban los beneficios sobre el ánimo y la conducta luego de manipular médica o quirúrgicamente la función reproductora de las mujeres. Más recientemente, los resultados de diversos estudios sugieren que los esteroides gonadales regulan el ánimo en algunas mujeres. Es así como existe un considerable interés en el potencial papel de las terapias con hormonas de la reproducción en el manejo de la enfermedad depresiva, incluyendo tanto los trastornos del ánimo clásicos como aquéllos relacionados con la endocrinología de la reproducción. Se requiere de futuros estudios para determinar predictores de respuesta a terapias hormonales comparadas con agentes antidepresivos tradicionales y también para caracterizar la seguridad a largo plazo y los beneficios de estas terapias.

50. Kendall DA, Stancel GM, Enna SJ. Imipramine: effect of ovarian steroids on modifications in serotonin receptor binding. Science. 1981;211:1183-1185.
51. Menkes DB, Rasenick MM, Wheeler MA, Bitskensky MW. Guanosine triphosphate activation of brain adenylate cyclase: enhancement by long-term antidepressant treatment. Science. 1983;129:65-67.
52. Perez J, Tinelli D, Brunello N, Racagni G. CAMP-dependent phosphorylation of soluble and crude microtubule fractions of rat cerebral cortex after prolonged desmethylimipramine treatment. Eur J Pharmacol. 1989;172:305-316.
53. Ozawa H, Rasenick MM. Chronic electroconvulsive treatment augments coupling of the GTP-binding protein Gs to the catalytic moiety of adenylyl cyclase in a manner similar to that seen with chronic antidepressant drugs. J Neurochem. 1991;56:330-338.
54. Nestler EJ, Terwilliger RZ, Duman RS. Chronic antidepressant administration alters the subcellular distribution of cyclic AMP-dependent protein kinase in rat frontal cortex. J Neurochem. 1989;53:1644-1647.
55. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry. 1997;54:597-606.
56. Nibuya M, Nestler EJ, Duman RS. Chronic antidepressant administration increases the expression of cAMP response element-binding protein (CREB) in rat hippocampus. J Neurosci. 1996;16:2365-2372.
57. Condorelli DF, Dell’Albani P, Mudo G, Timmusk T, Belluardo N. Expression of neurotrophins and their receptors in primary astroglial cultures: induction by cAMP-elevating agents. J Neurochem. 1994;63:509-516.
58. Singh M, Meyer EM, Simpkins JW. The effect of ovariectomy and estrogen replacement on brain-derived neurotrophic factor messenger ribonucleic acid expression in cortical and hippocampal brain regions of female Sprague-Dawley rats. Endocrinology. 1995;136:2320-2324.

59. Sohrabji F, Miranda RC, Toran-Allerand CD. Estragon differentially regulates estrogen and nerve growth factor receptor mRNAs in adult sensory neurons. J Neurosci. 1994;14:459-471.
60. Panickar KS, Gau G, King MA, Rajakumar G, Simpkins JW. 17β-Estradiol attenuates CREB decline in the rat hippocampus following seizure. J Neurobiol. 1997;33:961-967.
61. Zhou Y, Watters JJ, Dorsa DM. Estragon rapidly induces the phosphorylation of the cAMP response element binding protein in rat brain. Endocrinology. 1996;137:2163-2166.
62. Sohrabji F, Greene LA, Miranda RC, Toran-Allerand CD. Reciprocal regulation of estrogen and NGF receptors by their ligands in PC12 cells. J Neurobiol. 1994;25:974-988.
63. Murphy DD, Cole NB, Segal M. Brain-derived neurotrophic factor mediates estradiol-induced dendritic spine formation in hippocampal neurons. Proc Natl Acad Sci U S A. 1998;95:11412-11417.
64. Epperson CE, Wisner KL, Yamamoto B. Gonadal steroids in the treatment of mood disorders. Psychosom Med. 1999;61:676-697.
65. Bancroft J. The premenstrual syndrome—a reappraisal of the concept and the evidence. Psychol Med. 1993;(suppl 24):1-47.
66. Rubinow DR. The premenstrual syndrome: new views. JAMA. 1992;268:1908-1912.
67. Wyatt K, Dimmock P, Jones P, Obhrai M, O’Brien S. Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review. BMJ. 2001;323:1-8.
68. Freeman E, Rickels K, Sondheimer SJ, Polansky M. Ineffectiveness of progesterone suppository treatment for premenstrual syndrome. JAMA. 1990;264:349-353.

Clinical research

Traitements hormonaux de la fonction reproductrice utilisés pour les troubles de l’humeur chez la femme

Depuis plus d’un siècle, la médecine a pensé que la fonction reproductrice, aussi bien chez l’homme que chez la femme, était intimement liée avec la régulation de l’humeur. Le XIXe siècle fut le témoin d’une pléthore de textes affirmant les effets bénéfiques sur l’humeur et le comportement de manipulations médicales ou chirurgicales de la fonction reproductrice féminine. Plus récemment, les résultats de plusieurs études ont suggéré que les stéroïdes gonadales régulaient l’humeur de certaines femmes. Le rôle potentiel des traitements de la fonction reproductrice présente ainsi un intérêt considérable dans la prise en charge de la maladie dépressive, tant sur le plan des troubles de l’humeur classiques que de ceux liés à l’endocrinologie de la reproduction. Les études à venir devront déterminer les facteurs prédictifs des réponses aux thérapies hormonales comparés aux traitements antidépresseurs classiques et définir la tolérance à long terme et les bénéfices de ces traitements.

50. Kendall DA, Stancel GM, Enna SJ. Imipramine: effect of ovarian steroids on modifications in serotonin receptor binding. Science. 1981;211:1183-1185.
51. Menkes DB, Rasenick MM, Wheeler MA, Bitskensky MW. Guanosine triphosphate activation of brain adenylate cyclase: enhancement by long-term antidepressant treatment. Science. 1983;129:65-67.
52. Perez J, Tinelli D, Brunello N, Racagni G. CAMP-dependent phosphorylation of soluble and crude microtubule fractions of rat cerebral cortex after prolonged desmethylimipramine treatment. Eur J Pharmacol. 1989;172:305-316.
53. Ozawa H, Rasenick MM. Chronic electroconvulsive treatment augments coupling of the GTP-binding protein Gs to the catalytic moiety of adenylyl cyclase in a manner similar to that seen with chronic antidepressant drugs. J Neurochem. 1991;56:330-338.
54. Nestler EJ, Terwilliger RZ, Duman RS. Chronic antidepressant administration alters the subcellular distribution of cyclic AMP-dependent protein kinase in rat frontal cortex. J Neurochem. 1989;53:1644-1647.
55. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry. 1997;54:597-606.
56. Nibuya M, Nestler EJ, Duman RS. Chronic antidepressant administration increases the expression of cAMP response element-binding protein (CREB) in rat hippocampus. J Neurosci. 1996;16:2365-2372.
57. Condorelli DF, Dell’Albani P, Mudo G, Timmusk T, Belluardo N. Expression of neurotrophins and their receptors in primary astroglial cultures: induction by cAMP-elevating agents. J Neurochem. 1994;63:509-516.
58. Singh M, Meyer EM, Simpkins JW. The effect of ovariectomy and estrogen replacement on brain-derived neurotrophic factor messenger ribonucleic acid expression in cortical and hippocampal brain regions of female Sprague-Dawley rats. Endocrinology. 1995;136:2320-2324.

59. Sohrabji F, Miranda RC, Toran-Allerand CD. Estragon differentially regulates estrogen and nerve growth factor receptor mRNAs in adult sensory neurons. J Neurosci. 1994;14:459-471.
60. Panickar KS, Gau G, King MA, Rajakumar G, Simpkins JW. 17β-Estradiol attenuates CREB decline in the rat hippocampus following seizure. J Neurobiol. 1997;33:961-967.
61. Zhou Y, Watters JJ, Dorsa DM. Estragon rapidly induces the phosphorylation of the cAMP response element binding protein in rat brain. Endocrinology. 1996;137:2163-2166.
62. Sohrabji F, Greene LA, Miranda RC, Toran-Allerand CD. Reciprocal regulation of estrogen and NGF receptors by their ligands in PC12 cells. J Neurobiol. 1994;25:974-988.
63. Murphy DD, Cole NB, Segal M. Brain-derived neurotrophic factor mediates estradiol-induced dendritic spine formation in hippocampal neurons. Proc Natl Acad Sci U S A. 1998;95:11412-11417.
64. Epperson CE, Wisner KL, Yamamoto B. Gonadal steroids in the treatment of mood disorders. Psychosom Med. 1999;61:676-697.
65. Bancroft J. The premenstrual syndrome—a reappraisal of the concept and the evidence. Psychol Med. 1993;(suppl 24):1-47.
66. Rubinow DR. The premenstrual syndrome: new views. JAMA. 1992;268:1908-1912.
67. Wyatt K, Dimmock P, Jones P, Obhrai M, O’Brien S. Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review. BMJ. 2001;323:1-8.
68. Freeman E, Rickels K, Sondheimer SJ, Polansky M. Ineffectiveness of progesterone suppository treatment for premenstrual syndrome. JAMA. 1990;264:349-353.
Hormonal therapies for depression in women - Schmidt and Rubinow

69. Freeman EW, Rickels K, Sondheimer SJ, Polansky M. A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA. 1995;274:51-57.

70. Schmidt PJ, Nieman LK, Grover GN, Muller KL, Merriam GR, Rubinow DR. Lack of effect of induced menses on symptoms in women with premenstrual syndrome. N Engl J Med. 1991;324:1174-1179.

71. Cullberg J. Mood changes and menstrual symptoms with different gestagens/estrogen combinations: a double-blind comparison with a placebo. Acta Psychiatr Scand. 1972;236(suppl):1-86.

72. Kutner SJ, Brown WL. The relationship between retrospective premenstrual symptoms reporting and present oral contraceptive use. J Psychosom Res. 1987;31:45-53.

73. Lewis A, Houghugh M. An evaluation of depression as a side effect of oral contraceptives. Br J Psychiatry. 1969;115:897-701.

74. Woods NF, Most A, Dery GK. Prevalence of perimenstrual symptoms. Am J Public Health. 1992;72:1257-1264.

75. Marriott A, Faragher EB. An assessment of psychological state associated with the menstrual cycle in users of oral contraception. J Psychosom Res. 1986;30:41-47.

76. Slade P. Premenstrual emotional changes in normal women: fact or fiction? J Psychosom Res. 1984;28:1-17.

77. Smith RN, Studd JWW. Prevalence of menstrual syndrome. Am J Obstet Gynecol. 1987;31:45-53.

78. Cullberg J. Relationship between premenstrual symptoms and oral contraceptive use: a controlled study. Psychosom Med. 1990;52:86-96.

79. Woods NF, Most A, Dery GK. Prevalence of perimenstrual symptoms. Am J Public Health. 1992;72:1257-1264.

80. Marriott A, Faragher EB. An assessment of psychological state associated with the menstrual cycle in users of oral contraception. J Psychosom Res. 1986;30:41-47.

81. Slade P. Premenstrual emotional changes in normal women: fact or fiction? J Psychosom Res. 1984;28:1-17.

82. Cullberg J. Prevalence of menstrual cycle symptom cyclicity and premenstrual dysphoric disorder in a random sample of women using and not using oral contraceptives. Acta Obstet Gynecol Scand. 2001;79:405-413.

83. Walker A, Bancroft J. Relationship between premenstrual symptoms and oral contraceptive use: a controlled study. Psychosom Med. 1990;52:86-96.

84. Bancroft J, Rennie D. The impact of oral contraceptives on the experience of perimenstrual mood, clumsiness, food craving, and other symptoms. J Psychosom Res. 1993;37:195-202.

85. Backstrom T, Hansson-Malmstrom Y, Lindhe BA, Cavalli-Jokmark B, Nordenstrom S. Oral contraceptives in premenstrual syndrome: a randomised comparison of triphasic and monophasic preparations. Contraception. 1992;46:253-268.

86. Andersch B, Hahn L. Premenstrual complaints. II. Influence of oral contraceptives. Acta Obstet Gynecol Scand. 1981;60:579-583.

87. Freeman EW, Sondheimer SJ, Weinsaib PJ, Rickels K. Evaluating premenstrual symptoms in medical practice. Obstet Gynecol. 1985;65:500-505.

88. Graham CA, Sherwin BB. A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. J Psychosom Res. 1992;36:257-266.

89. Graham CA, Sherwin BB. The relationship between mood and sexuality in women using an oral contraceptive as a treatment for premenstrual symptoms. Psychoneuroendocrinology. 1993;18:273-281.

90. Freeman EW, Kroll R, Rapkin A, et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Women's Health Gend Based Med. 2001;10:561-569.

91. Watson NR, Savvas M, Studd JWW, Garnett T, Barber RJ. Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet. 1989;2:730-732.

92. Watson NR, Studd JWW, Savvas M, Barber RJ. The long-term effects of estradiol implant therapy for the treatment of premenstrual syndrome. Gynecol Endocrinol. 1990;4:199-207.

93. Smith RNJ, Studd JWW, Zambrana D, Holland EFN. A randomised comparison over 8 months of 100 mg and 200 mg twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. Br J Obstet Gynaecol. 1995;102:475-484.
119. Eriksson E, Ljus P, Sundblad C, Andersson K, Andersch B, Modig K. Effect of clomipramine on premenstrual syndrome. Acta Psychiatr Scand. 1990;81:87-88.

120. Sundblad S, Modig K, Andersch B, Eriksson E. Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial. Acta Psychiatr Scand. 1992;85:39-47.

121. Su TP, Schmidt PJ, Danaceau MA, et al. Fluoxetine in the treatment of premenstrual dysphoria. Neuropsychopharmacology. 1997;16:346-356.

122. Freeman EW, Rickels K, Sondheimer SJ, Denis A, Pfeiffer S, Weil S. Nefazodone in the treatment of premenstrual syndrome: a preliminary study. J Clin Psychopharmacol. 1994;14:180-186.

123. Henshaw C, Foreman D, Belder J, Cox J, O'Brien S. Can one induce premenstrual symptomatology in women with prior hysterectomy and bilateral oophorectomy? J Psychosom Obstet Gyn. 1996;17:21-28.

124. Halbreich U, Endicott J, Goldstein S, Nee J. Premenstrual changes and changes in gonadal hormones. In: Studd J, ed. Appleby L, Montgomery J, Studd J. Oestrogens and affective disorders. Oxford, UK: Blackwell Science; 1994:39:68-75.

125. Klaiber EL, Broverman DM, Vogel W, Kobayashi Y. Estrogen therapy for oestradiol therapy in menopausal depression. Arch Gen Psychiatry. 1987;1:297-299.

126. Lawrie TA, Hofmeyr GJ, Delager M, Berk M, Paiker J, Viljoen E. A double-blind randomized placebo controlled trial of postnatal norethisterone enanthate: the effect on postnatal depression and serum hormones. Br J Obstet Gynaecol. 1998;105:1082-1090.

127. Schmidt PJ, Rubinow DR. Mood and the perimenopause. Contemp Obstet Gyn. 1994;39:68-75.

128. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.

129. Schmidt PJ, Nieman L, Danaceau MA, et al. Estrogen replacement in perimenopausal depression: a preliminary report. Am J Obstet Gynecol. 2000;183:414-420.

130. Soares CD, Almeida OP, Joffe H, Cohen LS. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry. 2001;58:529-534.

131. Schmidt PJ, Murphy JH, Danaceau MA, Simpson-St Clair L. Basal plasma human levels in depressed perimenopausal women. Psychoneuroendocrinology. In press.

132. Coope J. Is oestrogen therapy effective in the treatment of menopausal depression? J Coll Gen Pract. 1981;31:134-140.

133. Campbell S. Double-blind psychometric studies on the effects of natural estrogens on post-menopausal women. In: Campbell S, ed. The Management of the Menopause and Post Menopausal Years. Lancaster, UK: MTP Press; 1976:149-158.

134. George GCW, Utitian WH, Beumont PJV, Beardwood CJ. Effect of exogenous oestrogens on minor psychiatric symptoms in postmenopausal women. S Afr Med J. 1973;47:2387-2388.

135. Montgomery JC, Brinca T, Mapp A, et al. Effect of oestrogen and testosterone implants on psychological disorders in the climacteric. Lancet. 1987;1:297-299.

136. Saletu B, Brandstatter N, Metka M, et al. Double-blind, placebo-controlled, hormonal, sydromal and EEG mapping studies with transdermal oestradiol therapy in menopausal depression. Psychopharmacology. 1995;122:321-329.

137. Cherwin BB. Affective changes with estradiol and androgen replacement therapy in surgically menopausal women. J Affect Disord. 1988;14:177-187.

138. Klaiber EL, Brownman DM, Vogel W, Kobayashi Y. Estrogen therapy for severe persistent depressions in women. Arch Gen Psychiatry. 1979;36:550-554.

139. Ditkoff EC, Cray WG, Cristo M, Lobo RA. Estragen improves psychological function in asymptomatic postmenopausal women. Obstet Gynecol. 1991;78:991-995.

140. Zwiebel LF, O'Brien WH. A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinology. 1997;22:189-212.

141. Spitzer RL, Kroenke K, Linzer M, et al. Health-related quality of life in primary care patients with mental disorders: results from the PRIME-MD 1000 study. JAMA. 1995;274:1511-1517.

142. Appleby L, Montgomery J, Studd J. Oestrogens and affective disorders. In: Studd J, ed. Progress in Obstetrics and Gynaecology. Edinburgh, UK: Churchill Livingstone; 1981:289-302.

143. Bloch M, Daly RC, Rubinow DR. Endocrine factors in the etiology of postpartum depression. Compr Psychiatry. 2002. In press.

144. Bloch M, Schmidt PJ, Danaceau M, Murphy J, Nieman L, Rubinow DR. Effects of gonadal steroids in women with a history of postpartum depression. Am J Psychiatry. 2000;157:824-930.

145. Dalton K. Progesterone prophylaxis used successfully in postnatal depression. Practitioner. 1985;229:507-508.

146. Dalton K. Depression After Childbirth. Oxford, UK: Oxford University Press; 1980.

147. Lawrie TA, Hofmeyr GJ, Delager M, Berk M, Paiker J, Viljoen E. A double-blind randomized placebo controlled trial of postnatal norethisterone enanthate: the effect on postnatal depression and serum hormones. Br J Obstet Gynaecol. 1998;105:1082-1090.

148. Michal DA, Cohen LS, Robertson LM, Ruttenberg A, Rosenbaum JF. Prophylactic estrogen in recurrent postpartum affective disorder. Biol Psychiatry. 1995;38:814-818.

149. Gregoire AJP, Kumar R, Everitt B, Henderson AF, Studd JWW. Transdermal oestrogen for treatment of severe postnatal depression. Lancet. 1996;347:930-933.

150. Akosas A, Kaukoranta J, Wahlbeck K, Aito M. Estrogen deficiency in severe postpartum depression: successful treatment with sublingual physiologic 17β-estradiol: a preliminary study. J Clin Psychiatry. 2001;62:332-336.

151. Rubinow DR, Roy-Byrne PP. Premenstrual syndromes: overview from a methodologic perspective. Am J Psychiatry. 1984;141:163-172.

152. Rubinow DR, Schmidt PJ. Mood disorders and the menstrual cycle. J Reprod Med. 1987;32:389-394.

153. Meyers BS, Moline ML. The role of estrogen in late-life depression: opportunities and barriers to research. Psychopharmacol Bull. 1997;33:289-291.

154. Lebowitz BD, Pearson J, Schneider LS, et al. Diagnosis and treatment of depression in late life: consensus statement update. JAMA. 1997;278:1186-1190.

155. Plourde L, J, Simon JA. Androgen effects on the central nervous system in the postmenopausal woman. Semin Reprod Endocrinol. 1998;16:135-143.

156. Schneider LS, Small GW, Hamilton SH, Bystritsky A, Nemeroff CB, Meyers BS. Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. J Am Geriatr Psychiatry. 1997:57;97-106.

157. Small GW, Schneider LS, Holman S, Bystritsky A, Meyers BS, Nemeroff CB. Estrogen plus fluoxetine for geriatric depression. Abstracts of the American Psychiatric Association 147th Annual Meeting. Los Angeles, Calif. May 1994. 1994;203.

158. Amsterdam J, Garcia-Espana F, Fawcett J, et al. Fluoxetine efficacy in menopausal women with and without estrogen replacement. J Affect Disord. 1999;55:11-17.

159. Shiffrin JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med. 2000;342:682-688.

160. Cohen AJ. Antidepressant-induced sexual dysfunction associated with low serum free testosterone. Psychiatry On-Line. 1999:1-5.

161. Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab. 1984;59:551-555.

162. Burger HG, Dudley EC, Cui J, Dennerstein L, Hopper JL. A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. J Clin Endocrinol Metab. 2000;85:2832-2838.

163. Snyder PJ. The role of androgens in women. J Clin Endocrinol Metab. 2001;86:1006-1007.

164. Wolkowitz OM, Reus VI, Roberts E, et al. Dehydroepiandrosterone (DHEA) treatment of depression. Biol Psychiatry. 1997;41:311-318.

165. Bloch M, Schmidt PJ, Danaceau MA, Adams LF, Rubinow DR. Dehydroepiandrosterone treatment of mid-life dysthymia. Biol Psychiatry. 1999;45:1533-1541.
166. Rabkin JG, Ferrando SJ, Wagner GJ, Rabkin R. DHEA treatment for HIV+ patients: effects on mood, androgenic and anabolic parameters. Psychoneuroendocrinology. 2000;25:53-68.

167. Goggin K, Engelson ES, Rabkin JG, Kotler DP. The relationship of mood, endocrine, and sexual disorders in human immunodeficiency virus positive (HIV+) women: an exploratory study. Psychoam Med. 1998;60:11-16.

168. Grinspoon S, Corcoran C, Miller K, et al. Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting. J Clin Endocrinol Metab. 1997;82:1332-1337.

169. Rabkin JG, Wagner GJ, Rabkin R. A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch Gen Psychiatry. 2000;57:141-147.

170. Daly RC, Schmidt PJ, Roca CA, Rubinow DR. Testosterone’s effects not limited to mood. Letter to the editor. Arch Gen Psychiatry. 2000;57:60-65.

171. Cummings SR, Browner WS, Bauer D, et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. N Engl J Med. 1998;339:733-738.

172. Rubino DR, Schmidt PJ, Zhang L, et al. Gonadal steroids and serotonergic: development and treatment of mood disorders. Abstracts of the 7th World Congress in Biological Psychiatry. Nice, France. June 1997.

173. Bethea CL, Pecins-Thompson M, Schutzer WE, Gundlah C, Lu ZN. Ovarian steroids and serotonin neural function. Mol Neurobiol. 1998;18:87-123.

174. Bethea CL, Gundlah C, Mirkes SJ. Ovarian steroid action in the serotonergic neural system of macaques. 2000 Neuronal and Cognitive Effects of Oestrogens, Chichester, UK: J. Wiley; 2000:399-410.

175. Roca CA, Schmidt PJ, Greenberg BD, Murphy DL, Rubinow DR. Serotonin and the efficacy of estrogen in perimenopausal depression. Abstracts of the 54th Annual Meeting of the Society of Biological Psychiatry. Washington DC. May 1999. 1999;45:765.

176. Krezel W, Dupont S, Kruetz A, Chambon P, Chapman PF. Increased anxiety and synaptic plasticity in estrogen receptor β-deficient mice. Proc Natl Acad Sci U S A. 2001;98:12278-12282.

177. Osterlund MK, Gustafsson JA, Keller E, Hurd YL. Estrogen receptor β (ERβ) messenger ribonucleic acid (mRNA) expression within the human forebrain: distinct distribution pattern to ERα mRNA. J Clin Endocrinol Metab. 2000;85:3840-3846.

178. Gundlah C, Kohama SG, Mirkes SJ, Garyfallou VT, Urbanski HF, Bethea CL. Distribution of estrogen receptor beta (ERβ) mRNA in hypothalamus, midbrain and temporal lobe of spayed macaque: continued expression with hormone replacement. Mol Brain Res. 2000;76:191-204.

179. Negro-Vilar A. Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J Clin Endocrinol Metab. 1999;84:3459-3462.

180. Katzenellenbogen BS, Choi I, Delage-Mouroux R, et al. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology. J Steroid Biochem Mol Biol. 2000;74:279-285.

181. Verbeek PM, Herpen A, Veen C, Groothuis PG. Progesterone receptor modulators: cell and sub-cell specificity in agonism and antagonism. Abstracts of the 83rd Annual Meeting of the Endocrine Society. Denver, Co. June 2001;163.

182. Wiehle RD, Newby C, Kelleher PJ. The search for SPRMs (selective progesterone receptor modulators). Abstracts of the 83rd Annual Meeting of the Endocrine Society. Denver, Co. June 2001. 2001;163.

183. Michelson D, Stratakis C, Reynolds J, Galliven E, Chrousos G, Gold P. Bone mineral density in women with depression. N Engl J Med. 1996;335:664-666.

184. Knopp RH, Zhu X. Multiple beneficial effects of estrogen on lipoprotein metabolism. J Clin Endocrinol Metab. 1997;82:3952-3954.

185. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340:1801-1811.

186. Walker BR. Steroid metabolism in metabolic syndrome X. Best Pract Res Clin Endocr Metab. 2001;15:111-122.

187. Krishnan KRR, Hays JC, Blazer DG. MRI-defined vascular depression. Am J Psychiatry. 1997;154:497-501.